[Optimized negative pressure therapy. Case report].
Our patient showed major abdominal cutaneous necrosis. Detersion removed the entire thickness of half of the right-hand wall of the abdomen. We are going to explain how, by combining well known procedures, we conducted this closure. This deals with a patient aged 53, with a long case history of dermatomyositis and highly debilitating sub-cutaneous calcinosis. This patient has been treated with Imurel and high doses of corticoids since 1997. In the face of the much debilitated terrain of the patient, it was not certain that a local flap or even a pediculated flap could be made to cover this loss of substance with a minimum of risk. A cutaneous extension was then envisaged using a system of Wisebands fillets. To protect the parietal plate, accelerate its growth and reduce the skin tension, we used in combination a system of foam dressing with negative pressure therapy (NPT). The optimized NPT was used for 2 weeks. The Wisebands were installed for 1 month. The treatment lasted for 50 days and required five short sessions of general anaesthesia. The histopathological interpretation revealed an EBV lymphoma. The assessment of the extension and the therapeutic treatment of the lymphoma contributed to the duration of hospitalisation and the number of general anaesthesia sessions. The synergy effect of these two associated procedures have allowed a faster skin closure; 18 months later, no complications have occurred. The wound has closed totally and the abdominal wall is solid in spite of not having resorted to a flap or separation.
Drossard
G
G
Service de chirurgie plastique reconstructrice et esthétique, CHU d'Angers, 4, rue Larrey, 49100 Angers, France. Dr.GuillaumeDrossard@mac.com
Potier
B
B
Steff
M
M
Rousseau
P
P
Payement
G
G
Darsonval
V
V
D034861:Abdominal Wall / Q000473:pathology / Q000601:surgery*; D000305:Adrenal Cortex Hormones / Q000009:adverse effects; D002114:Calcinosis / Q000150:complications; D003882:Dermatomyositis / Q000150:complications; D005260:Female; D006801:Humans; D016867:Immunocompromised Host; D007166:Immunosuppressive Agents / Q000009:adverse effects; D007902:Length of Stay; D008223:Lymphoma / Q000150:complications; D008875:Middle Aged; D009336:Necrosis; D054843:Negative-Pressure Wound Therapy / Q000379:methods*; D040521:Subcutaneous Tissue / Q000473:pathology / Q000601:surgery*; D014945:Wound Healing
D000305:Adrenal Cortex Hormones; D007166:Immunosuppressive Agents